Similar response rates were observed in B-cell and T-cell NHL, with several exceptional responders noted, underscoring the importance of rational study design which considers the genetic and molecular context of patient responses, as well as relevant biomarkers implicated in the pathogenesis of hematologic malignancies to identify patients most likely to benefit from PI3K inhibitor therapy. The gene discussed is PIK3CD; the disease is T-cell non-Hodgkin lymphoma.